Codexis and Nestlé Health Science enter new health partnership

By Catherine Sturman
Protein engineering company Codexis, Inc has recently partnered with Nestlé Health Science in a large number of projects, such as the development of en...

Protein engineering company Codexis, Inc has recently partnered with Nestlé Health Science in a large number of projects, such as the development of enzyme, CDX-6114 and management of phenylketonuria (PKU), an orphan metabolic disorder. 

 The deal will see Codexis receive an upfront payment of $14 million and potential milestones and royalties depending on product success. Codexis’ technology enables the implementation of biocatalytic solutions to meet customer needs.  Nestlé Health Science will also receive access to the CodeEvolver protein engineering platform as part of the agreement.

Codexis will be eligible to receive clinical development, approval and commercial milestone payments related to CDX-6114 as well as tiered royalties on product sales.  However, the company will remain responsible for the clinical development costs. 

Related stories

“This transaction validates our CodeEvolver protein engineering platform technology as a biotherapeutic discovery engine, and also highlights our ability to establish customized partnerships for unlocking the power of proteins with a growing list of the world’s great companies,” said John Nicols, Codexis President and Chief Executive Officer. 

“Enzymes are key to healthy functioning. When enzymes are not present or not working properly there can be an impairment of a wide range of processes critical for human health,” commented Greg Behar, Chief Executive Officer of Nestlé Health Science.

“The partnership with Codexis strengthens our footprint in the enzyme field, a fast developing part of the nutritional therapy innovation frontier that is changing the way we manage our health.”

Share

Featured Articles

McKinsey: Women More Likely to die of Heart Attack Than Men

McKinsey Health Institute's Lucy Pérez says cardiovascular disease top killer of women yet physicians don't know their heart attack symptoms are different

Novo Nordisk Buys $1bn Cardior in CardioVascular Move

As Novo Nordisk expands into heart medicines, we profile the Danish pharma giant who in 1923 was the first to make insulin commercially available

Shoddy Chinese Syringes Sees BD Ramp-up Production

Becton Dickinson – a major supplier of syringes – said it has upped manufacturing in its US facilities after FDA warning on China-made products

AI Tool 'Picks up Early-stage Breast Cancers Doctors Missed'

Technology & AI

AstraZeneca Buys $2bn Fusion in Next-gen Cancer Drugs Move

Medical Devices & Pharma

Eli Lilly and Amazon Pharmacy Partner on Drugs Delivery

Digital Healthcare